Drug-induced liver injury associated with Complementary and Alternative Medicine: a review of adverse event reports in an Asian community from 2009 to 2014 by Desmond Chun Hwee Teo et al.
RESEARCH ARTICLE Open Access
Drug-induced liver injury associated with
Complementary and Alternative Medicine:
a review of adverse event reports in an
Asian community from 2009 to 2014
Desmond Chun Hwee Teo1, Patricia Suet Leng Ng2, Siew Har Tan2, Adena Theen Lim2, Dorothy Su Lin Toh2,
Sui Yung Chan1 and Han Hui Cheong1,3*
Abstract
Background: The use of Complementary and Alternative Medicine (CAM) has been increasing over the years. A
recent review of adverse event reports (AERs) associated with CAM in Singapore found a notable number of AERs
submitted. The objectives of this study are to analyse hepatotoxicity cases associated with CAM in Singapore based
on spontaneous adverse event reporting to the Health Sciences Authority (HSA), and to highlight safety signals for
specific herbal ingredients.
Methods: AERs associated with CAM and hepatotoxicity submitted to the Vigilance and Compliance Branch (VCB)
of the HSA from 2009 to 2014 were compiled. The following information was extracted and analysed: Demographic
information; time to onset; hospitalisation status; outcome; type of hepatotoxicity; ingredients of CAM, and the total
daily doses (TDD); concurrent western medicines and health supplements; and reporter details.
Results: Fifty-seven reports were eligible for analysis. Thirty-five (61.4 %) cases involved Traditional Chinese
Medicine (TCM). The Roussel Uclaf Causality Assessment Method was applied in 29 (82.9 %) of these cases, and the
median score was 4 (range: 1–8). Chai Hu (Radix bupleuri) was suspected in 11 (31.4 %) cases. TDDs of most
ingredients were within recommended doses of the Chinese Pharmacopoeia.
Conclusions: Drug-induced liver injury is still poorly understood and more objective assessments are warranted.
Reporting of adverse events should be strongly advocated to facilitate future analyses and the understanding of
risk-benefit profiles of CAM.
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Background
CAM is a group of diverse medical and health care sys-
tems, practices, and products that are not presently con-
sidered to be part of conventional medicine [1]. Globally,
CAM is used in up to 50 and 80 % of the population in
developed and developing countries respectively [2, 3]. Its
popularity has increased rapidly since the 1990s [4–6].
This expanding usage of CAM has been attributed to a
number of factors [4, 6, 7], such as the increasing evidence
of its efficacy in palliative care [8–11], the belief that it is a
more holistic and well-rounded form of therapy [12, 13];
as well as a lower socioeconomic burden when compared
to using western pharmaceuticals [14]. However, a high
utilisation of CAM has also been associated with delays in
seeking conventional or western, medical treatment [15].
In Singapore, CAM is broadly termed as Complemen-
tary Health Products (CHP), which consists three main
categories: Chinese Proprietary Medicines (CPM), health
supplements and other traditional medicines [16]. For
the purpose of this study, the term CAM refers to CHPs.
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CAM use in Singapore was found to be high, in particu-
lar CPM and TCM, even amongst non-Chinese ethnic
groups [17]. As of 31 Dec 2014, there were 10,344 CPM
products listed in the database of the HSA, Singapore.
Under the Medicines Act of Singapore, CPMs refer to
any medicinal products that have been manufactured into
finished dosage forms (e.g. tablets, capsules) and used ac-
cording to the TCM system of therapeutics [18]. These
products can be from herbal, animal or mineral sources.
Dealers who import, manufacture or market CPMs are
required to list their products with the HSA, and ensure
compliance with the regulatory requirements [19].
CAM, like western medicines, can also present with
adverse effects, although they may generally be mistaken
as safer than their western counterparts [7, 17, 20]. A
study on AERs submitted to the HSA from 1998 to 2009
reviewed 627 cases associated with CAM and 80.2 % of
these were found to be serious [21]. In previous studies
of drug-induced liver injury (DILI) trends in Singapore
conducted by Wai et al., CAM accounted for 22 out of
31 (71.0 %) and 15 out of 29 (52.0 %) cases of hepatotox-
icity [22, 23]. This accentuates the possible severity of
DILI related to CAM.
Diagnosis and clinical evaluation of DILI is particularly
challenging, and has been a popular topic of debate
amongst clinicians, academia, regulators and pharmaceut-
ical companies [24]. Clinicians often rely on diagnostic
markers such as aminotransferase levels and physical
examinations to make an initial evaluation. Viral markers,
history of alcoholism, signs of biliary obstruction, compli-
cations of underlying diseases such as sepsis, or chronic
viral hepatitis are also typically evaluated in order to rule
out other possible causes of liver injury. In spite of these,
it is usually difficult to evaluate DILI appropriately [25].
Causality assessment becomes more complicated when
DILI cases are also confounded by pre-existing medical
conditions, concomitant western medicines, underlying
liver pathology and other factors. Objective scales are thus
utilised where possible to complement case evaluations.
The Roussel Uclaf Causality Assessment Method
(RUCAM) was created based on the international DILI
consensus criteria [26]. It applies numerical weightages
to essential features of DILI in seven different domains
[27, 28]. An overall score is generated and interpreted as
a causality probability. The RUCAM is structured, quan-
titative, liver-specific, and validated for use in hepatotox-
icity [29]. It has been shown to be more accurate and
reproducible when compared to other causality assess-
ment tools like the Naranjo scale [30, 31] and the Maria
and Victorino scale [32].
This study aimed to analyse hepatotoxicity cases associ-
ated with the use of CAM, through a critical review of
AERs in the Singapore’s National Pharmacovigilance Ad-
verse Drug Reaction (ADR) database managed by the HSA.
In particular, the ingredients of CPM and TCM products
were analysed to identify any potential safety signals that
could be associated with them. By studying these DILI
cases, this study could better facilitate the surveillance of
CAM products and promote their safe and effective use.
Methods
This study was reviewed and approved by the National
University of Singapore Institutional Review Board
(NUS-IRB) (Approval number: NUS 2383; NUS-IRB ref-
erence code: B-14-229). A confidentiality agreement was
also signed with the HSA for access to confidential
information in the Pharmacovigilance ADR database and
to safeguard the information received in the course of
this project.
Sources of data
AERs were submitted to the VCB of the HSA through
the “Suspected Adverse Drug Reactions” form. The form
contains multiple fields for entry by the health care pro-
fessional or company reporting the adverse event, such
as the patient’s demographic information, reporter’s de-
tails, details of the AE or ADR, management of the ad-
verse event, as well as other relevant information. These
reports were submitted by e-mail, facsimile, postal mail,
or electronically through the Critical Medical Informa-
tion Store (CMIS) component of the Electronic Medical
Record Exchange (EMRX).
Submitted forms were reviewed by regulatory special-
ists of the VCB. These reports were examined for caus-
ality of the suspected drug or herb. Any information
that was lacking or unclear were clarified with the re-
porters, and documented accordingly. All related mate-
rials and documents to each report were stored within
the Pharmaceutical Regulatory Information System
(PRISM) database. The information was also used in
aggregate analysis. As a member of the World Health
Organisation (WHO) International Drug Monitoring
Programme, these reports are submitted to the Uppsala
Monitoring Centre (UMC) in Sweden for collation into
WHO’s VigiLyze [33].
Data mining and e-collation
Adverse event(s) in each report were categorised using
the WHO Adverse Reaction Terminology (WHO-ART).
Filters were used to obtain the desired reports for the re-
view. The System Organ Class chosen was “Liver and
Biliary System Disorders”. “Complementary Medicines”,
“CPM”, and “Health Supplements” were selected as the
type of product involved, and the inclusion period was
from 1st January 2009 to 31st December 2014 based on
the date of receipt of the AER by the VCB. The
WHO-UMC organisation system for standardised case
causality assessment was also used. Only reports with
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the causality terms “certain”, “probable” or “possible”,
as assessed by the VCB, were included for analysis.
Reports that were associated with adulterated CAM
products, assessed by the VCB as “unlikely” or “un-
confirmed”, or had missing critical information such
as ingredient lists or names of products, were excluded
from the study. The statuses of all reports are updated as
of 31st Jan 2015.
The following information were extracted from the
reports and compiled into a Microsoft® Excel spreadsheet:
(1) Demographic information (i.e. age, gender, and ethni-
city); (2) Date of onset and time to onset for the adverse
event; (3) Hospitalisation status of the patient; (4) Out-
come of the adverse event; (5) Type of hepatotoxicity
involved; (6) Ingredients of all CAM products used, and
the TDD of each ingredient; (7) Details of any concurrent
western medicines; and (8) Profession of the reporter.
Hospitalisation status of the patients were categorised as
“hospitalised”, “not hospitalised” and “already hospitalised”.
The term “already hospitalised” describes patients who
have been admitted for other co-morbidities prior to the
adverse event. The outcomes of the events were classified
into “recovered”, “not yet recovered”, “uncertain outcome”
and “death”. The type of hepatotoxicity in the cases were
classified according to the phenotypes of DILI, as described
in the LiverTox database by the National Institute of Dia-
betes and Digestive and Kidney Diseases (NIDDK) [34]. A
brief description of the different phenotypes is shown in
Table 1. Western medicines that were consumed by the
patient at the same time or within 3 months before the
date of receipt of AER were considered as concomitant
medications. To ascertain the likelihood of DILI in the
cases for review, only CAM products that were used within
the 3-month period prior to the date of receipt of AER
Table 1 Phenotypes of Hepatotoxicity
Phenotypes of DILI Brief description a
Acute hepatic necrosis Clinical course resembles an acute, toxic injury to the liver with sudden and precipitous onset,
marked elevations in serum aminotransferase (ALT, AST) levels, and early signs of hepatic (or
other organ) dysfunction or failure despite minimal or no jaundice. Rapid recovery after
withdrawal of the agent is also typical. It is typically caused by a direct hepatotoxin and is
usually dose dependent and “expected”, rather than idiosyncratic.
Acute hepatitis Course of illness resembles acute viral hepatitis with insidious onset, a hepatocellular pattern
of injury and jaundice. Illness typically lasts 2 to 4 weeks and ultimately resolves, but severe
instances can result in acute liver failure and death.
Cholestatic hepatitis Course of illness is marked by cholestasis, even early at the time of onset. The liver enzyme
pattern is cholestatic with prominence of ALP and bilirubin elevations. The illness can be
prolonged.
Mixed hepatocellular-cholestatic hepatitis Course of DILI is considered “mixed” if features of both hepatocellular and cholestatic injury
are present. The liver enzyme pattern is characterized by moderate to marked elevations in
ALT, AST and ALP, such that the R ratio b is between 2 and 5.
Enzyme elevations without jaundice The most commonly observed form of DILI is the elevation of ALT, AST or ALP (or all) without
jaundice and with minimal or no symptoms.
Bland cholestasis The course of illness is marked by prominent and typically prolonged jaundice and
cholestasis with minimal serum enzyme elevations or evidence of hepatocellular necrosis.
Hepatic steatosis and lactic acidosis The hallmark of this syndrome is hepatic microvesicular steatosis accompanied by lactic
acidosis, with clinical and laboratory features of hepatic failure, such as encephalopathy.
Nonalcoholic fatty liver Nonalcoholic fatty liver disease and steatohepatitis are well documented but rare forms of
DILI. In addition, fatty liver disease is more often chronic than acute even when it is drug
induced.
Chronic hepatitis The course of illness resembles chronic viral hepatitis with serum aminotransferase elevations
without jaundice and with mild symptoms if any. ALT and AST levels may fluctuate over time
and intermittently fall into the normal range.
Sinusoidal obstruction syndrome Sinusoidal obstruction syndrome, or veno-occlusive disease, is a distinctive and potentially
fatal form of hepatic injury that occurs predominantly, if not only, after drug or toxin
exposure.
Nodular regenerative hyperplasia This condition typically presents with the insidious or unexpected onset of signs or
symptoms of portal hypertension in a patient with little evidence of chronic liver disease.
Hepatic adenoma and hepatocellular carcinoma Tumours of the liver include benign tumours such as hepatic adenomas, and malignant
cancers such as hepatocellular carcinoma and cholangiocarcinoma.
ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, DILI drug-induced liver injury, ULN upper limit of normal
a Descriptions of the various phenotypes of hepatotoxicity were adapted from the NIDDK LiverTox Database [34]
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were considered for analysis. The variables collected from
the AERs were analysed using descriptive statistics.
Amongst the CAM ingredients compiled, those sus-
pected to be associated with hepatotoxicity, either through
expert opinion from the VCB or from previous docu-
mented reports in established databases such as LiverTox
and the China Food and Drug Administration (CFDA),
were further examined in detail. References to tertiary lit-
erature such as the Chinese Pharmacopoeia and textbooks
on complementary medicines were also made. The
RUCAM [27, 28] was employed to review the likelihood
of these ingredients causing hepatotoxicity in the patients.
The updated version of RUCAM was used to calculate
the scores of the case reports [35, 36]. For cases with
concomitant western medicines reported, the RUCAM
was also used to evaluate the causality of those medi-
cines with documented evidence of hepatotoxicity in
the literature.
Results
A total of 842 AERs associated with CAM were received
by the HSA between the period of 2009 to 2014, of
which 76 (9.0 %) involved hepatotoxicity. Based on the
inclusion and exclusion criteria, 57 (75.0 %) of the 76
AERs involving liver injury were analysed. Figure 1
shows the year-on-year trend of AERs associated with
CAM. On average, about 140 reported cases were linked
to CAM every year, and about 9 % of these AERs in-
volved hepatotoxicity.
There were 28 male (49.1 %) and 29 female (50.9 %)
patients in the 57 liver injury case reports that were
assessed. Majority (73.7 %) of them were above 40 years
of age. Forty-seven (82.5 %) patients were of Chinese
ethnicity. More than half (70.2 %) of the patients were
hospitalised due to the adverse events. Thirty-three
(57.9 %) patients had not recovered based on the latest
report. Five (8.8 %) cases resulted in death. Demograph-
ics and other pertinent information extracted from the
AERs are shown in Table 2.
Most of the cases (61.4 %) involved TCM, followed
by health supplements (28.1 %), and other traditional
medicines (10.5 %) which included Malay Jamu and In-
dian Ayurveda products. For simplicity, the use of the
term “TCM” here refers to both CPM and traditional
Chinese remedies that are not finished products.
Amongst the cases involving TCM products (n = 35), a
total of 312 different Chinese herbal ingredients were
compiled and analysed. The most common herbs found
were Fu Ling (Sclerotium poriae cocos) (18 cases), Huang
Qin (Radix scutellaria baicalensis) (15 cases), Gan Cao
(Radix glycyrrhizae) (15 cases), Ze Xie (Alisma orientalis)
(14 cases) and Chuan Xiong (Rhizoma ligustici) (14 cases).
These herbs are described in Table 3.
The distribution of the type of hepatotoxicity reported is
shown in Table 4. Majority (59.6 %) of the cases reported
acute hepatitis as the main adverse event. Cholestatic
hepatitis, on the other hand, was seen only in three
(5.3 %) cases. There were no reports of hepatic adenoma
or hepatocellular carcinoma. In general, CAMs were used
by these patients to promote health and well-being (6
cases), for slimming and weight control (9 cases), and
minor ailments (22 cases) such as cough, gastrointestinal
complaints and pain relief. Five patients used CAM for
liver-related conditions e.g. jaundice, abdominal disten-
sion; and strengthening of liver function. Among herbal
ingredients which were previously reported in the litera-
tures as possible hepatotoxic agents [37–53], some of
those found were Chai Hu (Radix bupleuri) (11 cases), Da
Huang (Radix et rhizoma rhei) (6 cases), Chuan Lian Zi
(Fructus toosendan) (2 cases), Hu Zhang (Radix polygoni
cuspidati) (2 cases), and He Shou Wu (Radix polygoni
multiflori) (1 case), and are elaborated in Table 5.
Fig. 1 Number of AER associated with CAM received by HSA between 2009 and 2014. A total of 842 AERs associated with CAM were received by
the HSA between the period of 2009 to 2014, of which 76 (9.0 %) involved hepatotoxicity
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Twenty-nine (82.9 %) of the 35 cases had sufficient
information for the computation of a RUCAM score.
The median score for these reports was 4, with a range
of 1 to 8. The interpretation of the scores are as fol-
lows: 0 or less indicates that the drug is “excluded” as a
cause; 1 to 2 that it is “unlikely”; 3 to 5 “possible”; 6 to
8 “probable”; and greater than 8, “highly probable”. The
RUCAM score for the remaining 6 cases were not
available due to a lack of essential information, such as
the time to onset, transaminase levels and whether any
exclusion tests e.g. viral markers, antibody titres, were
performed to rule out alternative causes of hepatotoxicity.
Concurrent use of western medicines was also re-
ported in 30 (52.6 %) of the cases, where 16 (53.3 %) of
them contained active pharmaceuticals that are poten-
tially hepatotoxic. Some of these examples are the sta-
tins, fibrates, paracetamol, and phenytoin. The RUCAM
scores were calculated for 10 (62.5 %) of these 16 cases,
and the median was 1 (range: 0 to 5).
Discussion
Through this study, the patterns of hepatotoxicity associ-
ated with the use of CAM were analysed over a 6-year
period from 2009 to 2014. In general, an average of 140
cases related to CAM was reported yearly, and about 9 %
of these involved hepatotoxicity.
Demographic information of the adverse event reports
There was no difference in the gender distribution of the
AERs. This is opposed to previous findings that women
were more likely to be affected by adverse reactions to drug
treatment [39, 54, 55]. Differences in endogenous and ex-
ogenous hormones, body size and fat compositions, and
also liver metabolism were cited as possible reasons for the
gender differences. A woman’s reproductive function may
also increase the need for medications at an earlier age than
men, increasing the likelihood of adverse drug reactions
[55]. In this study, the small sample size of 57 reports may
be insufficient to conclude whether there are any gender
differences predisposing to hepatotoxicity. Furthermore,
only one patient used CAM to regulate menstruation, and
none for contraceptive or reproductive purposes.
Majority (73.7 %) of the patients were above 40 years of
age, and there was no significant differences (p = 0.755) in
the gender distribution in this age group (19 males, 23
females). Age has been cited as a risk factor for hep-
atotoxicity due to the increased likelihood of comorbid
conditions and deteriorating organ function, especially
the liver [41, 56]. Therefore it is not unexpected that a
Table 2 Demographic and characteristics of AERs received between 1st Jan 2009 and 31st Dec 2014
Demographics & information of patients No. of cases, n (%) Characteristics of adverse event reports No. of cases, n (%)
1. Gender 5. Profession of Reporter of Adverse Event
Female 29 (50.9) Doctor 51 (89.5)
Male 28 (49.1) Pharmacist 4 (7.0)
2. Age in years Nurse 0 (0.0)
< 1 2 (3.5) Drug Company 2 (3.5)
1–20 2 (3.5) Others 0 (0.0)
21–40 11 (19.3) 6. Outcome of Adverse Event
41–60 26 (45.6) Recovered 12 (21.1)
> 60 16 (28.1) Not recovered 33 (57.9)
3. Ethnicity Death 5 (8.8)
Chinese 47 (82.5) Uncertain Outcome 7 (12.3)
Malay 7 (12.3) 7. Type of CAM a implicated
Indian 1 (1.8) Traditional Chinese Medicine 35 (61.4)
Others 1 (1.8) Health supplements 16 (28.1)
Information not available 1 (1.8) Other Traditional Medicines 6 (10.5)
4. Hospitalisation Status
Hospitalised 40 (70.2)
Not hospitalised 12 (21.1)
Already hospitalised 3 (5.3)
Information not available 2 (3.5)
Total number of reports included in data analysis, N = 57
Assumption: a 3 categories of CAM: (1) Traditional Chinese Medicine (includes both CPM and traditional Chinese remedies); (2) Health supplements; (3) Other
traditional medicines (includes Malay Jamu and Indian Ayurveda). Cosmetic products were excluded
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large proportion of cases involved patients above
40 years old. Nonetheless, under-reporting of DILI is
still a prevalent phenomenon in many countries [57,
58] and the demographic characteristics of patients in
this study may not accurately reflect those found in
prospective cohort studies of DILI.
Types of CAM implicated and outcomes of adverse events
The proportions of different types of CAM used were
similar to other studies conducted in Singapore [17, 59,
60]. TCM accounted for the majority of CAM usage,
followed by health supplements, regardless of ethnicity.
TCM, was implicated in 61.4 % of the adverse events.
The major affected ethnic group was the Chinese (82.5 %).
These findings are congruent with the earlier review of
AERs associated with complementary medicines and
health supplements [21]. The study found that CPMs and
Chinese patients were more commonly implicated in ad-
verse events than other CAMs and ethnic groups. The
reason for these similar findings could be attributed to the
widespread availability and relatively easy accessibility of
TCM products in Singapore where the population is 80 %
of Chinese ethnicity.
Assessment of DILI cases involving TCM
Among the 35 cases involving TCM products, RUCAM
scores were calculated for 29 (82.9 %), with a median score
of 4 and range of 1 to 8. Only Chinese herbal ingredients
Table 4 Phenotypes of hepatotoxicity reported with the corresponding CAM implicated and outcome of AE
Phenotypes of DILI a No. of cases, n (%) Type of CAM implicated (n) Outcome of AE (n)
Acute hepatitis 34 (59.6) TCM (22), Health supplements (7),
Other traditional medicines (5)




9 (15.8) TCM (6), Health supplements (3) Not recovered (5), Recovered (2), Uncertain
outcome (2)
Acute hepatic necrosis 5 (8.8) TCM (4), Health supplements (1) Death (1), Recovered (1) Not recovered (3)
Cholestatic hepatitis 3 (5.3) TCM (2), Health supplements (1) Death (1), Not recovered (1), Recovered (1)
Mixed hepatocellular-
cholestatic hepatitis
3 (5.3) TCM (1), Health supplements (1),
Other traditional medicines (1)
Not recovered (2), Recovered (1)
Chronic hepatitis 2 (3.5) Health supplements (2) Death (1), Not recovered (1)
Nonalcoholic fatty liver 1 (1.8) Health supplements (1) Uncertain outcome (1)
Total number of reports included in data analysis, N = 57
AE adverse event, CAM complementary and alternative medicine, DILI drug-induced liver injury, TCM Traditional Chinese Medicine
a Phenotypes of hepatotoxicity were adapted from the NIDDK LiverTox Database [34]









Mechanisms of action (based on
TCM system of therapeutics) a
Recommended
daily doses (g) a
Fu Ling
(Sclerotium poriaecocos)
18 (31.6) Acute hepatic necrosis (3), Acute
hepatitis (11), Cholestatic hepatitis
(1), Mixed hepatocellular-cholestatic
hepatitis (1), Enzyme elevations
without jaundice (2)
8.3 (13.4) Promotes urination in order to drain
dampness, strengthens the spleen




15 (26.3) Acute hepatic necrosis (3), Acute
hepatitis (10), Mixed hepatocellular-
cholestatic hepatitis (1), Enzyme
elevations without jaundice (1)
6.3 (12.1) Clears heat and dries dampness, purges





15 (26.3) Acute hepatic necrosis (3), Acute
hepatitis (8), Mixed hepatocellular-
cholestatic hepatitis (1), Enzyme
elevations without jaundice (3)
8.9 (10.6) Strengthens spleen and improves 'qi',
clears heat and removes toxin, dispels
phlegm in order to relieve cough, relax





14 (24.6) Acute hepatic necrosis (2), Acute
hepatitis (11), Mixed hepatocellular-
cholestatic hepatitis (1)
5.9 (14.4) Promotes urination to drain dampness,





14 (24.6) Acute hepatic necrosis (1), Acute
hepatitis (10), Mixed hepatocellular-
cholestatic hepatitis (1), Enzyme
elevations without jaundice (2)
6.3 (8.3) Activates blood and moves 'qi', and
dispels wind in order to relief pain.
3–10
Total number of reports included in data analysis, N = 57
Abbreviations used: TCM Traditional Chinese Medicine, TDD total daily doses of raw herb (in grams)
a Information is obtained from the Pharmacopoeia of the People’s Republic of China, 9th Ed, 2010 (English Ed)
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Mechanisms of action (based on
TCM system of therapeutics) a
Recommended
daily doses (g) a
Chai Hu
(Radix bupleuri)
11 (19.3) Acute hepatitis (9), Acute hepatic
necrosis (2)
18.0 (33.5) Disperses and reduces fever, soothes the





8 (14.0) Acute hepatitis (3), Acute hepatic
necrosis (2), Cholestatic hepatitis
(1), Enzyme elevations without
jaundice (1), Mixed hepatocellular-
cholestatic hepatitis (1)
7.9 (15.5) Reduces ‘dampness’, strengthens the
spleen, dispels ‘wind’ and dissipates
‘cold’, and improves vision
3–9
Zhi Ban Xia (Rhizoma
pinelliae ternatae
preparata)
7 (12.3) Acute hepatitis (3), Acute hepatic
necrosis (2), Enzyme elevations
without jaundice (2)
5.7 (3.4) Reduces ‘dampness’ and phlegm,
suppresses counteractive flow (e.g.
vomiting), dissolves lumps and
reduces masses
3–9
Xi Xin (Radix et
rhizome asari)
7 (12.3) Acute hepatitis (4), Acute hepatic
necrosis (1), Enzyme elevations
without jaundice (2)
2.2 (1.6) Dispels ‘wind’ and dissipates ‘coldness’,
dispels ‘wind’ and relieves pain, relieves
blocked nose, warms the




6 (10.5) Acute hepatitis (3), Acute hepatic
necrosis (1), Enzyme elevations
without jaundice (1), Mixed
hepatocellular-cholestatic
hepatitis (1)
8.1 (15.2) Removes accumulation of waste materials
through purging, clears ‘heat’ and purges
‘fire’, cools the blood and removes toxins,
expel stasis in order to unblock the





4 (7.0) Acute hepatitis (2), Acute hepatic
necrosis (1), Enzyme elevations
without jaundice (1)
3.7 (1.2) Promotes sweating and dissipates ‘cold’,
diffuse the lungs to relieve panting, and




3 (5.3) Acute hepatitis (2), Cholestatic
hepatitis (1)
1.1 (1.3) Clears ‘heat’ and purges ‘fire’, gives rise to





2 (3.5) Acute hepatic necrosis (1),
Acute hepatitis (1)
0.7 (N/A b) Clears ‘heat’ and dry ‘dampness’, dispels




2 (3.5) Acute hepatitis (1), Enzyme
elevations without jaundice (1)
0.7 (0.7) Clears ‘heat’ and improves vision,
‘moistens the intestines to promote
bowel movement
9–15
Chuan Lian Zi (Fructus
toosendan)
2 (3.5) Acute hepatitis (2) 1.2 (N/A b) Soothes the liver and discharges ‘heat’,
move ‘qi’ to relieve pain, kill worms
5–10
Cang Er Zi (Fructus
xanthii sibirici)
2 (3.5) Acute hepatitis (2) 4.7 (4.7) Disperses coldness caused by wind,





2 (3.5) Acute hepatitis (2) 4.6 (4.8) Reduces ‘dampness’ to abate jaundice,
clears heat and removes toxins, dissipates





2 (3.5) Acute hepatic necrosis (1),
Acute hepatitis (1)
1.9 (1.6) Dispels ‘wind’ and removes ‘dampness’,
relieves pain
3–10
He Shou Wu (Radix
polygoni multiflori)
1 (1.8) Acute hepatitis (1) 1.0 (N/A) Removes toxins, disperses abscesses,
manage malaria, and ‘moistens’ the
intestines to promote bowel movement
3–6
Zhi He Shou Wu
(Radix polygoni multiflori
praeparata)
1 (1.8) Acute hepatitis (1) 1.8 (N/A) Strengthens the liver and kidney,
replenishes essence and blood, darkens
beard and hair, strengthens sinew and
bone, and reduces lipid levels
6–12
Total number of reports included in data analysis, N = 57
Abbreviations used: TCM Traditional Chinese Medicine, TDD total daily doses of raw herb (in grams)
a Information is obtained from the Pharmacopoeia of the People’s Republic of China, 9th Ed, 2010 (English Ed)
b Standard deviations for Bai Xian Pi (Dictamni cortex) and Chuan Lian Zi (Fructus toosendan) were not available due to insufficient dosing information
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that were previously reported in the literature as possibly
risky for liver injury (Table 5) were assessed for causality.
The range of scores indicates causalities of unlikely, pos-
sible or probable. None of these cases had a score of 0 or
less, which suggests that the likelihood of hepatotoxicity
for these TCM cannot be entirely ruled out. Notwithstand-
ing the range of scores obtained for these 29 cases, a
proper evaluation of causality for these DILI cases was
challenging and hard to ascertain.
In addition, most of the patients used at least ten dif-
ferent ingredients, and the duration of use ranged from
a few months to 3 years. The use of multiple products
over an extended period of time could have produced a
heavy metabolic burden on the liver. This could predis-
pose the patients to acute liver injuries, regardless of the
presence of potentially hepatotoxic ingredients.
Chinese herbal ingredients taken at recommended
doses by the Chinese Pharmacopoeia typically do not
present harm to the liver, though it is unclear whether
prolonged use or abrupt changes in the dosage can pre-
cipitate hepatotoxicity. In this study, most of the TCM
ingredients were used within their recommended dose
ranges. There were two patients that used a number of
ingredients beyond their recommended daily doses;
some examples were Dang Gui (Radix angelicae sinen-
sis), Dang Shen (Radix codonopsis) and Chai Hu (Radix
bupleuri). Among these ingredients, only Chai Hu was
previously reported in the literature as potentially hep-
atotoxic [37, 43, 47, 61]. However, due to the advanced
age of both patients (70 and 83 years old), coupled with
the use of numerous herbal products over a prolonged
period, it was hard to pinpoint specific agents that could
have caused DILI.
Accurate naming of the correct plant species and spe-
cific plant part is also crucial for an appropriate assess-
ment. Unfortunately, AERs rarely provide sufficient
details on the plant family, subfamily, species, subspecies
or variety used. This specification is necessary as hepato-
toxic chemicals may be distributed unevenly throughout
some plants [62]. For example, if rhizomes of a plant are
prescribed, additional clarification is needed on whether
the peeled or unpeeled rhizome was used, the extent of
peeling, as well as whether any adjacent parts were in-
cluded in the herbal product. The degree of processing
may also influence the toxicity of a plant species, such
as He Shou Wu (Radi polygoni multiflori), where the
processed form (Zhi He ShouWu [Radix polygoni multi-
flori praeparata]) would be less hepatotoxic and higher
daily doses could be recommended. Variations in these
aspects could have affected the toxicity potential of dif-
ferent formulations, and in turn influence the outcome
of causality assessments [44].
With the regulation of CPMs in Singapore, many of these
factors influencing the accuracy of herbal hepatotoxicity
assessments can be mitigated to a certain extent. The pro-
cesses of listing CPM products for regulatory approval
ensures manufacturers and importers accurately report the
specific ingredients and amounts within each product [63].
Requirements on labelling, prohibited claims, types of test
reports, quality parameters are needed before a CPM can
be listed.
As no CPM is 100 % safe, DILI can occur with no
plausible explanations. For example, the Chinese herbal
plant Chai Hu (Radix bupleuri) is traditionally used to
treat liver-related conditions such as jaundice, and is
said to disperse liver ‘qi’ stagnation and reduce damp-
ness. However, Chai Hu had been implicated in multiple
cases of acute hepatitis both as an ingredient alone and
within a particular formulation “Xiao Chai Hu Tang” (also
known as Syo-Saiko-To in Japanese) [37, 43, 47, 61]. The
incidences had been linked to the consumption of Chai Hu
for prolonged periods of time, even at therapeutic doses,
and evaluated as possible to probable causality. Addition-
ally, the mentioned reports ruled out other possible causes
of liver injury, as well as any quality and manufacture is-
sues of the Chai Hu-containing products. In this study, 11
cases with Chai Hu as one of the suspected ingredients
were identified. The mean TDD was 18.0 ± 33.5 g, which
was more than the Chinese Pharmacopoeia recommended
range of 3 to 10 g. However, there was a large variability in
the TDD among the 11 cases, with minimum and max-
imum daily doses of 0.2 g and 100 g respectively. Differ-
ences in the clinical course and presence of confounders in
the cases could have complicated the evaluation process
and made it difficult to establish a general observation.
Therefore, the likelihood of hepatotoxicity with Chai Hu
could not be adequately addressed.
Another patient, where a causality assessment of “cer-
tain” was assigned, experienced abdominal pain, poor
appetite, dark coloured urine and malaise for about
10 days, after taking TCM for about 1 month. She was
advised to discontinue the TCM products because of the
possibility of DILI. About 6 months later, she took TCM
once again and developed liver injury after 3 days of
consumption. Investigations did not establish any abnor-
mal aetiology and the hepatitis resolved after supportive
treatment. The temporal relationship on multiple occa-
sions, along with the exclusion of other possible causes,
gave a strong indication of possible TCM-induced DILI.
However, due to the wide range of herbal ingredients
which the patient was taking, it was difficult to pinpoint
any exact causative agents, making any conclusive as-
sessment highly challenging.
DILI remains poorly understood and are often
neglected. The limited body of knowledge presents a
major clinical and regulatory challenge for appropriate
assessment of causal factors. Although expert opinion
from clinicians and regulatory authorities remain the
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mainstay for conducting evaluations, more objective
methods such as probability scales and mathematical
models may be necessary to supplement causality
evaluation [24]. A recent review of systematic reviews
involving DILI associated with CAM had shown the
importance of including case reports and series in
these reviews, in order to obtain a more holistic inter-
pretation of the available evidence [64].
RUCAM Scores for concomitant western medicines
It was necessary to rule out the influence of western
pharmaceuticals with reported hepatotoxicity in the lit-
erature. Sixteen out of the 57 cases were reviewed for
confounding effects by western medicines. The RUCAM
was used for 10 of these 16 cases, and the median score
was 1 (range: 0 to 5). RUCAM scores were not comput-
able for the remaining 6 cases due to a lack of informa-
tion. Among the 10 cases, there was only one case with
a score of 5, while the scores for the other 9 were from
0 to 2. This means that for most of the cases, causality
for the western medicines were either excluded or un-
likely. From these observations, it was unlikely that the
western medicines used attributed to the adverse reac-
tions reported.
Limitations of the study
Lack of necessary information
The retrospective design of this study limited the
amount of information that could be collected and ana-
lysed. Details of the indication of CAM products, posol-
ogy and administration, actual periods of use and other
necessary information were often incomplete or even
lacking. Furthermore, most of the patients were on mul-
tiple types of CAM. Reporters or patients might also
have been unwilling to share certain information they
deemed sensitive. Poor monitoring of administration
timelines by patients, in particular the elderly were likely
(28.1 % of the cases were above 60 years old). In
addition, product information such as the source and
manufacturer details was missing in some cases. For
TCM products that are not regulated as CPMs, specifi-
cations on the plant parts used and the processing or
preparation methods were lacking. The poor standard-
isation of information across the 57 reports made it
challenging to analyse them under a common denomin-
ator. This could lead to a misinterpretation or oversim-
plification of the data obtained.
Presence of confounders
The issue of insufficient information was further com-
pounded by the presence of multiple confounders in the
patients, such as pre-existing liver diseases, alcoholism,
and the use of western medicines, which could have influ-
enced the causality assessment of hepatotoxicity to a
certain extent. Under-reporting is also commonly present
in spontaneous reporting systems, especially with the use
of CAM [40, 58]. Many patients might not have regarded
CAM as a “medicine” or might have been reluctant to
share information on such use with their health care pro-
viders. Furthermore, most CAM products were available
over-the-counter and patients need not seek the advice of
health professionals before using them.
Drug-herb interactions
The methodology of this study might have not been ro-
bust enough to pick up potential drug-herb, herb-herb,
or herb-food interactions, especially if patients were re-
luctant to share or neglected the importance of such in-
formation. The presence of interactions could confound
the assessment of hepatotoxicity in patients, as many
drugs/herbs were orally ingested and hence subjected to
hepatic first-pass. This could potentially lead to an over-
or underestimation of the causality of certain drugs or
herbs. It was therefore crucial to obtain a complete picture
of a patient’s pharmacotherapy in order to appropriately
assess DILI. Prospective designs could be explored to
evaluate individual herbs and their respective interactions.
Review of non-TCM CAM
As majority (61.4 %) of the adverse events involved TCM,
the primary analyses mainly looked at the different Chinese
herbal ingredients and their hepatotoxic potential. Infor-
mation regarding the other forms of CAM which include
but are not limited to the Malay Jamu, Indian Ayurveda
and the Perso-Arabic Unani medicine were limited and
hence the study was unable to thoroughly evaluate the risk
of hepatotoxicity for these fields of medicine. Although
Malay Jamu and Indian Ayurveda constituted 10.5 % of the
cases in the study, most of the ingredients either could not
be identified accurately or were largely dissimilar and no
particular ingredients stood out amongst the cases. None-
theless, further reviews could be conducted specifically for
these groups of CAM to detect potential signals of hepato-
toxicity or other adverse reactions.
Conclusions
In this study, we outline the patterns of hepatotoxicity as-
sociated with the use of CAM through a review of AERs.
In addition, AERs associated with TCM products were
looked at in detail, and Chinese herbal ingredients with a
high propensity for hepatotoxicity were highlighted. Pa-
tients who used CAM generally did not anticipate any risks
involved with their therapy, and were not strictly compliant
at all times. Majority of the health professionals were un-
able to evaluate the cases adequately due to insufficient in-
formation provided by the patients, as well as the lack of
extensive clinical evidence base for the CAM therapies.
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The findings suggest the need for improvement on pro-
spective evaluations of suspected DILI cases, preferably
with the aid of structured causality assessment tools. In
the modern era of patient-centred care, the notion of “evi-
dence-based medicine” is highly crucial. Clinical trials
have been increasingly conducted for CAM over the past
decades [65–69], and the efficacy of herbs such as ginger
(Zingiber officinale) and various ginseng species has been
well-established [66, 69]. Healthcare professionals play an
important role in spontaneous ADR reporting and moni-
toring the safety of CAM used by the population [70].
Their interactions with the AE reporting system to facili-
tate collection, monitoring and evaluation of adverse drug
events are highly crucial. Lastly, similar analyses could also
be conducted to evaluate the risk-benefit profiles of CAM
involving other organ systems.
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